Inactive Instrument

Guided Therapeutics Inc Stock price OTC Bulletin Board

Equities

US40171F2048

Advanced Medical Equipment & Technology

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for Guided Therapeutics Inc
Sales 2021 81K Sales 2022 13K Capitalization 14.58M
Net income 2021 -2M Net income 2022 -4M EV / Sales 2021 126 x
Net Debt 2021 2.26M Net cash position 2022 50K EV / Sales 2022 1,118 x
P/E ratio 2021
-3.19 x
P/E ratio 2022
-1.96 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 56.24%
More Fundamentals * Assessed data
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Guided Therapeutics, Inc. Announces CEO Changes CI
Guided Therapeutics, Inc. Announces Executive Changes CI
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Guided Therapeutics, Inc. Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guided Therapeutics, Inc. Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740 CI
More news
Managers TitleAgeSince
Founder 68 92-10-26
Founder 68 92-10-26
Members of the board TitleAgeSince
Director/Board Member 74 06-04-09
Director/Board Member 67 16-11-09
Founder 68 92-10-26
More insiders
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on the development of medical devices. The Company develops prototypes and conducts limited clinical studies using its biophotonic technology for the detection of esophageal cancer. Its primary focus is selling and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide an alternative to conventional tests for cervical cancer screening and detection. It is focused on two primary applications for LuViva: first, as a cancer screening tool and second, as a triage for various traditional screening.
More about the company
  1. Stock
  2. Equities
  3. Stock Guided Therapeutics, Inc.
  4. Stock Guided Therapeutics Inc - OTC Bulletin Board